Samsung BioLogics Acquires Swiss Peptide CDMO PolyPeptide, Target Price Set at 2M KRW

According to Daishin Securities, Samsung BioLogics announced the acquisition of Swiss peptide contract development and manufacturing organization (CDMO) PolyPeptide on July 21, expanding its business scope beyond antibodies into peptide therapeutics. Analyst Hong Ga-hye initiated coverage with a "Buy" rating and a 2 million Korean won price target, citing the acquisition as a new growth driver for the company.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments